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Abstract
Altered nucleoside levels may be linked to pathogenic signaling through adenosine recep-
tors. We hypothesized that adenosine dysregulation contributes to fibrosis in diabetic kid-
ney disease. Our findings indicate that high glucose levels and experimental diabetes
decreased uptake activity through the equilibrative nucleoside transporter 1 (ENT1) in proxi-
mal tubule cells. In addition, a correlation between increased plasma content of adenosine
and a marker of renal fibrosis in diabetic rats was evidenced. At the cellular level, exposure
of HK2 cells to high glucose, TGF-β and the general adenosine receptor agonist NECA,
induced the expression of profibrotic cell activation markers α-SMA and fibronectin. These
effects can be avoided by using a selective antagonist of the adenosine A3 receptor subtype
in vitro. Furthermore, induction of fibrosis marker α-SMA was prevented by the A3 receptor
antagonist in diabetic rat kidneys. In conclusion, we evidenced the contribution of purinergic
signaling to renal fibrosis in experimental diabetic nephropathy.
Introduction
Diabetes mellitus is produced by a chronic metabolic unbalance and its incidence rate has dra-
matically increased worldwide [1]. Diabetic nephropathy (DN) is a long-term complication
affecting up to 30–40% of diabetic patients and is the major cause of end-stage renal disease
worldwide [2]. DN is also a major risk factor for cardiovascular disease and can be a life threat-
ening condition. The economic and social impact of the illness is high, due to the fact that DN
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predisposes patients to undergo organ replacement therapies at advanced stages [3,4]. To date,
strict controls of glycaemia and arterial blood pressure as well as the use of blockers of the
renin-angiotensin system have only been modestly effective in slowing the evolution of DN [5].
Thus, DN remains incurable and there is an urgent demand for new therapies.
Incipient DN is characterized by the occurrence of podocytopathy and alterations in the fil-
tration barrier which are clinically evidenced by hyperfiltration and microalbuminuria. As the
disease advances an extensive renal fibrosis arises, characterized as a progressive and irrevers-
ible process [6]. A key event in this process is the transition of epithelial cells to a mesenchymal
phenotype (EMT) acquiring the properties to mediate renal fibrosis and probably migrate to
the interstitium. Typically, the expression of alpha smooth muscle actin (α-SMA) and fibro-
nectin have been used as markers of profibrotic cells activation. Emerging evidence has shown
that cytokines such as transforming growth factor-beta 1 (TGF-β), high glucose levels and
advanced glycation end products influence profibrotic activation in kidney cells phenotype
[7,8]. The discovery of mediators of this pathogenic process is a major current focus due to
their valuable therapeutic potential.
Recently, it was demonstrated that a systemic rise of plasma adenosine and derived metabo-
lites occurring in DN patients correlate with the progression of the disease, while the nucleo-
side levels were basal in diabetic patients without renal complication similar to those observed
in healthy people [9,10]. Extracellular adenosine arises from the adenine nucleotide metabo-
lism, thus becoming a crucial step the hydrolysis of AMP [11]. In addition, the equilibrative
nucleoside transporters (ENTs), recognized by their sodium-independent facilitative transport
activity, mediates the adenosine uptake to be metabolized intracellularly whereas nucleoside
can be accumulated outside when the transport activity is reduced. Consequently, it has been
described that ENTs could play a major contribution to adenosine availability for autocrine or
paracrine signaling through adenosine receptors [12–22]. Notably, the transition from the epi-
thelial to the mesenchymal phenotype was shown in the renal epithelial tubular cells line HK2
knocked down for the equilibrative nucleoside transporter member 1 (ENT1) [23]. These
observations suggest a link between altered adenosine handling and profibrotic activation of
cells. Adenosine modifies cell function by signaling via the P1 purinoceptor family [24]. While
A1 and A2A subtypes have high affinity for their ligand, the A2B and A3 receptors require
increased levels of adenosine to mediate a cellular response. Functionally, a protective role
for adenosine A2A receptor subtype in diabetic nephropathy by attenuating inflammatory
responses has been described [25]. Absence of A1 adenosine receptor results in an increase of
both the diabetic hyperfiltration and the glomerular damage, thus suggesting that it also plays a
protective task [26,27]. In contrast, the A2B receptor subtype mediates pathogenic events that
trigger diabetic glomerulopathy [22]. While a role for the A3 receptor subtype has been recently
associated with the progression of renal fibrosis in a model of chronic kidney disease [28], its
contribution to the pathogenesis of diabetic renal disease remains to be analyzed.
The goal of this study was determine the mechanism that mediates altered adenosine han-
dling in the diabetic kidney and its relation with purinergic signaling and renal fibrosis. We
provide evidence of a decreased adenosine uptake occurring in the epithelial tubule cells of the
diabetic kidney concomitant with the progression of renal disease. We also demonstrate the
contribution of adenosine receptor signaling to the phenotypic transition of cells.
Material and Methods
Materials
Pharmacological modulators of adenosine receptors and inhibitors of nucleoside transporters
were purchased from Tocris Biosciences. Culture mediums, serum, antibiotics and
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supplements were purchased from Invitrogen. Chemicals and streptozotocin were purchased
fromMerck KGaA. Tritiated adenosine was obtained from American Radiolabeled Chemicals.
Cell culture
Human proximal epithelial tubule cell line (HK2) was obtained from ATCC. The cells were
propagated in Keratinocyte Serum Free Medium (K-SFM) supplemented with 0.05 mg/ml of
bovine pituitary extract (BPE) and 5 ng/ml human recombinant epidermal growth factor
(EGF) and antibiotics, at standard condition of 5% CO2 at 37°C in a humidified atmosphere.
Animal models
Diabetes was induced in male rats (Sprague-Dawley) weighing 250 g by single intravenous
administration of streptozotocin (STZ) at 55 mg/kg dissolved in citrate buffer, pH 4.5. Controls
rats were injected with an equivalent volume of vehicle. The diabetic groups included animals
presenting blood glucose levels 25 mmol/L. Animals were monitored up to four months.
Also diabetic rats were treated with the adenosine A3 receptor antagonist MRS1220 at doses
0.1 mg/kg via intraperitoneal administration from days 31 to 60 post diabetes induction, and
animals were then sacrificed. Ent1 knockout mice were originally generated by Choi et al. [16].
Renal samples were obtained from the University of Barcelona´s own colony.
Ethics statement
All animal procedures were approved by the Institutional Committee on the Use of Live Ani-
mals in Research at the University Austral de Chile (Ref. 2012/59). Animal welfare was moni-
tored daily and all efforts were made to minimize suffering. Any animal showing signs of
limited movement or significant weight loss were euthanized by intra-peritoneal injection of
sodium thiopental (200 mg/kg body weight).
Human biopsies
Human renal samples were obtained from patients controlled in the nephrology department of
Fundació Puigvert, Barcelona, Spain. Use of samples was approved by the Comité Ético de
Investigación Clínica (CEIC) from Fundació Puigvert (Ref. 2010/19). Percutaneous kidney
biopsies from 9 diabetic patients with nephropathy and normal kidney tissue from 3 patients
affected by renal carcinoma were used for the study. The biopsies were obtained for diagnosis
in all patients before 2005, without further follow up in Fundació Puigvert, the study was sub-
mitted to ethic committee considering that following the current legislation, were not required
informed consent for participate in this study.
Proximal convoluted tubule (PCT) isolation
Renal PCT were extracted from healthy and diabetic rats as described previously [29]. The kid-
neys were perfused through the renal artery, first with Hank's Balanced Salt Solution (HBSS)
and then with HBSS containing 1mg/ml collagenase type II. Renal cortical slices were incu-
bated for 10 minutes with HBSS/collagenase and maintained at 37°C, 50 mg/ml BSA was then
added, maintaining the agitation for another 5 minutes. The homogenate was poured through
gauze to eliminate non digested tissue. The extracts were centrifuged at 300 x g for 3 minutes
and then the pellets were washed with HBSS without CaCl2 and centrifuged. The remaining
material was resuspended in 45% percoll (GE Health Care) in solution HBSS without CaCl2
and centrifuged at 7900 x g for 15 minutes at 4°C, obtaining 3 phases. The middle phase, con-
taining the PCT was extracted and washed. The pellet was diluted between 8 to 14 times
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depending of the amount. The PCT extracts were used immediately for transport activity
assays. Purity of extracts was assessed by detecting the enrichment of the PCT marker aqua-
porin 1 and loss of glomerular nephrin and podocin.
Nucleoside transport activity
HK2 cells were cultured in 24 well plates in presence of 5mM or 25mM glucose for 24 h. Nucle-
oside transport activity was assayed in choline buffer (in mM: 5.4 KCl, 1.8 CaCl2, 1.2 MgSO4,
10 Hepes, 137 choline chloride, pH 7.4) supplemented with [3H]-adenosine (2mCi/nmol) and
10μM of adenosine at 22°C. Incubation was stopped after 20 seconds by washing the monolay-
ers twice in 2 ml of cold buffer composed of 137 mM choline chloride and 10 mM Tris-Hepes,
pH 7.4. Cells were then lysed in 0.250 ml of 1M NaOH. Aliquots were taken for protein deter-
mination and for radioactivity counting. Particular uptake rates for equilibrative nucleoside
transporters 1 or 2 (ENT1, ENT2) were assigned to transport activities which were inhibited by
1 μM S-(4-nitrobenzyl)-6-thio-inosine (NBTI) or 2 mM hypoxanthine, respectively [30]. Total
nucleoside uptakes in cells mediated by concentrative and equilibrative systems were also mea-
sured using transport buffer containing sodium chloride. Sodium-dependent uptake rates were
obtained by subtracting adenosine uptakes in choline buffer to the total adenosine uptakes in
buffer containing sodium chloride.
Nucleoside transport activity in PCT
Freshly purified PCTs were incubated in 100μl of choline solution with or without NBTI or
hypoxanthine for 30 minutes. Nucleoside transport activity was assayed in choline buffer sup-
plemented with or without NBTI or hypoxanthine, with [3H]-adenosine (2mCi/nmol), and
20 μM of adenosine. The uptake of adenosine was assayed adding 100μl of solution with [3H]-
adenosine for 20 seconds at 22°C. Incubation was stopped by washing with 1ml of cold buffer
composed of 137 mM choline chloride and 10 mM Tris-Hepes (pH 7.4). Cells were then centri-
fuged at 12000 x rpm for 5 minutes at 4°C and washed again. After the second wash the pellet
was dissolved in 250μl of 0.5M HCOOH. Aliquots were sampled for protein determination and
for radioactivity counting.
Adenosine quantification
HK2 cells were cultured at 80% confluence under standard conditions in 6 well plates for 24 h.
The medium was then replaced for Tyrode buffer (10mMHEPES, 12mM NaHCO3, 137mM
NaCl, 2.7mM KCl, 5mM Glucose and 1mM CaCl2) supplemented with 2.5μM EHNA and
1μMNBTI for 1h. The adenosine content was quantified using derivatization with 2-chloroa-
cetaldehyde and HPLC with fluorometric detection [20]. The values were normalized to the
total amount of cellular proteins. For adenosine quantification in plasma of rats, samples of
blood were extracted in proportion 3:1 with STOP solution (10mM EDTA, 10mM EGTA,
1 mM dipyridamole and 2.5 μM EHNA) from caudal vein. Plasma samples were deproteinized
using 10% TCA, neutralized with 2 N KOH and treated with solution ZN/Ba [10]. Finally, sam-
ples were derivatized and quantified as described above.
Protein extracts
Total proteins were extracted with lysis buffer (2% SDS, 10% glycerol, 63.5 mM Tris HCl, pH
6.8) containing Complete Proteinase Inhibitor and 1μg/ml pepstatin (Roche). The proteins
were quantified using BCA protein assay kit (Thermo Scientific).
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Western blots
Protein extracts (50μg) were fractionated by 10% SDS-PAGE and transferred to PVDF mem-
branes. The blots were washed with wash buffer (PBS1x, 0.05% Tween20), blocked for 1 h with
0.1% BSA, and incubated with primary antibodies anti-fibronectin (SC-56391), anti-α-SMA
(SC-130617) or anti-Pro-COL1A2 (SC-8787) from SantaCruz Biotechnology, and anti-ENT1
from Protein Tech (II 337-1-A7). Primary antibodies against adenosine receptors were anti-
A1AR from Sigma, anti-A2AAR and anti-A2BAR from Abcam and anti-A3AR fromMillipore.
The membranes were washed and the primary antibodies were detected using HRP-coupled
secondary antibodies. A chemiluminescence procedure was used for the detection of the pro-
teins (Thermo Scientific). The protein levels were expressed as the ratio between the target pro-
tein and β-actin or tubulin detected in the same membrane.
siRNA
Adenosine A3 receptor subtype knockdown was achieved in HK2 cells using commercially
available and validated short interfering RNAs (siRNA) from Ambion catalogue number
AM16708. Cells seeded in 6-well plates (200,000) were transfected with 100 pmol of siRNA
using lipofectamine 3000. Following 24 h post-transfection the cells were exposed to transdif-
ferentiation stimuli and the expression of fibronectin was evaluated by western blot.
Immunohistochemistry
Rat and human kidney tissues were fixed in formalin, embedded in paraffinand 5 μm sections
were mounted on silanized slides. Immunodetections were performed as described previously
[20] using the primary polyclonal anti-ENT1 antibody from Protein Tech (II 337-1-A7) and
the monoclonal anti-αSMA (sc130617) and anti-A3AR (sc-13938) from Santa Cruz Biotech-
nology. The immunosignals were detected using the LSAB+ System–HRP (DakoCytomation).
Statistical methods
Values are means ± SD, where n indicates number of animals used or number of experiments
in cells each one in triplicates. Statistical analyses were carried out on raw data using the Peritz
F multiple means comparison test. Student’s t-test was applied for unpaired data.
Results
Diabetes modifies extracellular adenosine metabolism in epithelial
tubule cells
In order to characterize the mechanisms that control extracellular levels of adenosine, we ana-
lyzed the nucleoside uptake rates mediated by the nucleoside transporters in epithelial tubule
cells. Using the epithelial cell line HK2, derived from human proximal tubules, it was deter-
mined that the adenosine uptake activity was largely mediated by the equilibrative sodium-
independent transporters (ENTs) compared to the negligible activity mediated by the concen-
trative nucleoside transporters (CNTs). Particular uptake rates mediated by ENT1 or ENT2
subtypes could be individualized through selective inhibition with 1 μM S-(4-nitrobenzyl)-
6-thio-inosine (NBTI) or 2 mM hypoxanthine, respectively [30]. Thus, the uptake mediated by
the equilibrative nucleoside transporter-1 (ENT1) was far more significant in comparison to
the transport activity mediated by ENT2 in these cells (Fig 1A). Further, we mimicked the
effects of diabetes in HK2 cells by exposing them to high D-glucose concentrations. Upon
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exposure of HK2 to 25mM D-glucose, the ENT1-mediated uptake of adenosine decreased by
50% in comparison to 5mMD-glucose (Fig 1A).
To further assess the consequences of experimental diabetes on adenosine handling, proxi-
mal tubules were isolated from healthy and diabetic rats. Following the induction of experi-
mental diabetes in rats, glycemic levels were raised to values around 450 mg/dl, gaining of mass
was depressed and the kidney weight relative to the total body weight was increased which is
indicative of kidney hypertrophy (Table 1). The progression of renal injury was evidenced by
the detection of increasing levels of proteinuria and urea, manifestly higher than controls ani-
mals at 4 months post diabetes induction. In addition, nephropathy manifests with increased
uric acid levels, a metabolite generated from purines catabolism (Table 1). Furthermore, an
extensive abundance of the alpha-smooth muscle actin (α-SMA) was detected in the cortical
area of kidney from diabetic rats following four months of diabetes induction (Fig 2A). There-
fore, our analyses in tissue samples from rats following 1 and 4 months post diabetes induction
represent early and manifest stages of kidney injury respectively.
Adenosine uptake rates were found to be decreased by diabetes in isolated renal tubules due
to a lesser ENT1-mediated activity (Fig 1B), despite the fact that the content of ENT1 in rat
renal tissues was not altered by experimental diabetes (Fig 1C). Reduction of adenosine uptake
mediated by ENT1 was higher than 70% following one (0.230 ± 0.087 vs 0.060 ± 0.039 pmol
• μmoles prot-1 • min-1, P value< 0.01) and four (0.200 ± 0.047 vs 0.053 ± 0.019 pmol • μmoles
prot-1 • min-1, P value< 0.01) months from diabetes induction (Fig 1B). Remarkably, the con-
sequence of inhibition of ENT1 activity using NBTI resulted in a marked increase in extracellu-
lar adenosine levels in HK2 cells (Fig 1D).
Fig 1. Nucleoside transport activity in renal epithelial tubule cells. A. Total and particular [3H]adenosine transport activities were assayed in HK2 cells.
The effect of D-glucose concentration on transport activities was assayed in HK2 cells exposed to 5mM and 25mM for 24h. Total uptake activity mediated by
concentrative (CNTs) and equilibrative (ENTs) systems was obtained in transport buffer containing Na+; while ENTs-mediated uptake was determined by
using a Na+ free buffer. CNTs component was derived from the difference between total transport activity in Na+ containing buffer minus the transport activity
in Na+ free buffer. The graphs depict particular ENT1 mediated nucleoside uptake as the fraction of the transport in Na+ free buffer inhibited by 1μMNBTI,
while the ENT2 fraction that was inhibited by 2mM hypoxanthine. Data is expressed as mean ± SD of triplicate measurements from 20 independent assays.
* P < 0.05 versus 5mMD-glucose. B. Renal proximal tubules were isolated from vehicle- and STZ-treated rats following 1 and 4 months. The effect of
diabetes on sodium-independent transport uptake activities mediated by ENT1 and ENT2, was quantified. Data is expressed as mean ± SD of triplicate
measurements for assays using extracts from 5 animals in each group. * P < 0.05 versus control. C. The protein level of ENT1 in tubule extracts was
evaluated by western blot. Representative images of western blots using diabetic (db) and control (ctr) rat extracts are shown. The graph depicts the
mean ± SD of ratio between immune signals of ENT1 vs tubulin. The ratio in control extracts were normalized to 1. A statistically significant difference was not
found. n = 6. D. The extracellular adenosine levels were quantified in the medium of HK2 cells exposed to NBTI, an inhibitor of ENT1 activity. Data is
mean ± SD from 5 experiments. * P < 0.05 versus control.
doi:10.1371/journal.pone.0147430.g001
Table 1. Physiological parameters in streptozotocin-induced diabetic rats.
1 month 4 months
control diabetes control diabetes
Body weight (gr) 518 ± 53 315 ± 74 * 593 ± 115 284 ± 120 *
Glycaemia (mg/dl) 124 ± 21 449 ± 188 * 133 ± 99 482 ± 80 *
Relative kidney weight (g/Kg) Left 6.24 ± 0.6 10.6 ± 1.8 * 5.35 ± 0.3 10.93 ± 1.5 *
Right 5.47 ± 0.7 9.7 ± 1.9 * 5.32 ± 0.8 10.60 ± 1.7 *
Proteinuria (mg/mg creatinine) 1.8 ± 0.3 2.3 ± 0.6 2.5 ± 0.6 4.9 ± 0.6 *
Urinary Urea (mg/mg creatinine) 47.6 ± 5.9 50.4 ± 8.5 39.1 ± 3.5 87.0 ± 10.2 *
Urinary Uric Acid (mg/mg creatinine) 0.079 ± 0.083 0.140 ± 0.09 0.077 ± 0.03 0.172 ± 0.05 *
*, P < 0.05 diabetes vs control (n = 6).
doi:10.1371/journal.pone.0147430.t001
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Adenosine mediates profibrotic changes in epithelial tubule cells
A pivotal correlation was evidenced between the mark of the α-SMA, a sign of profibrotic cells
activation, and the increase of plasma levels of adenosine in diabetic rats (Fig 2B). Pearson cor-
relation value r was 0.7934 with P value< 0.01 (n = 28). Furthermore, kidneys isolated from
ent1-/- knockout mice showed higher levels of α-SMA (Fig 2C). Adenosine renal interstitial lev-
els have been found to rise in ent1-/- mice or animals treated with an inhibitor of its activity
[21]. Also, when cells were incubated with dipyridamole to block ENT transport activity, profi-
brotic changes were induced [23]. These observations suggest a link between altered adenosine
handling and profibrotic activation that remains to be elucidated.
The cellular effects of adenosine are mediated by the P1 family of purinergic receptors. The
four subtypes of adenosine receptors were found at RNA and protein levels in HK2 cells. The
exposure of HK2 cells to the general adenosine receptors agonist NECA induced the expression
of the profibrotic markers fibronectin, α-SMA and procollagen type I (Fig 3). These effects
were similar to those observed using high D-glucose (25mM) or TGF-β, recognized inducers of
profibrotic phenotypic transition in epithelial cells (Fig 3).
To characterize the adenosine receptor subtypes involved in profibrotic activation, HK2
cells were exposed to a set of selective pharmacological antagonists in conjunction with the
general agonist NECA. As shown in Fig 4, the induction of fibronectin and α-SMA mediated
by NECA can be blocked using MRS1220, the antagonist of adenosine A3 receptor subtype,
independent of the concentrations of D-glucose in the medium (Fig 4). In addition, the antago-
nist of the A1 receptor subtype blocked the induction of markers in cells exposed to 5mMD-
glucose but it was unable to reproduce these effects in cells exposed to a high D-glucose envi-
ronment (Fig 4). Interestingly, the profibrotic activation using TGF-β can be also blocked by
MRS1220 in this cell line in both 5 and 25 mMD-glucose conditions (Fig 5A). Further
demonstration of the role of the adenosine A3 receptor subtype was obtained from siRNA
Fig 2. Evidences of renal fibrosis in diabetic rats and ent1 knockout mice. A. Representative immunohistochemical detection of α-SMA in kidney
sections from vehicle- and STZ-treated diabetic rats. The arrows indicate interstitial and periglomerular staining. B. The graph depicts plasmatic adenosine
levels in control and diabetic rat groups. * P < 0.05 vs control, n = 6. C. Representative immunohistochemical detection of α-SMA in kidney sections from 8
weeks old ent1-/- and wild type mice. The graphs (A and C) show quantitative results derived from staining analyses of consecutive field from three animals
per group using the UN-SCANIT 2.0 software. Values of control or wild type samples were normalized to 1. * P < 0.05 vs control or wild type. Original
magnifications 200X.
doi:10.1371/journal.pone.0147430.g002
Fig 3. Phenotypic transition of HK2 cells. The induction of profibrotic markers α-SMA, fibronectin and pro-collagen were evaluated by western blot in HK2
cells treated for 24 h with the general agonist of adenosine receptors NECA (5 μM), TGF-β (2 ng/ml) and high D-glucose (25mM). Representative western
blots are shown.
doi:10.1371/journal.pone.0147430.g003
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experiments. In addition to prevent the induction of fibronectin mediated by NECA and high
D-glucose (S1 Fig), the knockdown of the A3 receptor subtype prevented HK2 cell transition in
5 and 25 mMD-glucose conditions TGF-β induced (Fig 5B).
In vivo evaluation of an adenosine A3 receptor antagonist in diabetic rats
The examination of the content of the adenosine receptors in HK2 cells by western blot analy-
sis indicates that the total levels were not affected by the exposure of cells to different D-glucose
concentrations (Fig 6A). Furthermore, the content of adenosine receptors in purified tubule
extracts did not change following 1 or 4 months post diabetes induction in rats (Fig 6B). There-
fore, the possibility to be pharmacologically modulated is conceivable. Following one month
post diabetes induction, diabetic rats were treated with MRS1220 or vehicle for 4 weeks.
Immune staining of α-SMA was significantly reduced in renal cortical tubules from
MRS1220-treated animals compared to vehicle-treated diabetic rats (Fig 7). Treatment with
the A3 receptor antagonist did not affect the increased plasma adenosine levels in diabetic rats
at this stage (data not shown).
Evaluation of ENT1 and adenosine A3 receptor in human diabetic
nephropathy
Whereas, the STZ-treated diabetic rat model permits the early evaluation of moderate kidney
injury, human DN progresses with an extensive renal fibrosis. To further evaluate the expres-
sion of ENT1 and the adenosine A3 receptor throughout the progression of human diabetic
kidney disease, immune detection of both proteins were carried out in biopsies from normal,
moderate and advanced kidney injury. Clinical parameters in patients are shown in S1 Table.
The distribution of α-SMA was used to show progression of kidney fibrosis in biopsies (Fig 8).
In the most severe renal tubule-interstitial fibrosis damage, glomerulosclerosis with low cellu-
larity and loss of tubular structures was evident. The ENT1 expression was mainly restricted to
tubular epithelium and some glomerular cells. This pattern was maintained with the progres-
sion of renal injury. The adenosine A3 receptor was located in the epithelial tubule cells, glo-
merular cells and Bowman’s capsule in normal tissue. Along with the lower glomerular
cellularity observed in advanced stages of renal injury, both the content of ENT1 and A3AR
were decreased in renal glomeruli. In contrast, the tubulointerstitial distribution of the adeno-
sine A3 receptor subtype was shown increased in human biopsies throughout the progression
of kidney injury (Fig 8).
Discussion
This study is the first show a link between profibrotic activation of renal epithelial tubule cells
with the activity of the adenosine A3 receptor in the context of diabetic renal disease. Thus, the
purpose of our research was i) to demonstrate the role of high glucose on altered nucleoside
handling in proximal tubule epithelial cells, ii) correlate lower nucleoside uptake activity medi-
ated by ENT1 with increased adenosine levels and iii) to connect increased ligand levels with
Fig 4. An antagonist of adenosine A3 receptor blocks NECA-induced profibrotic markers. The particular adenosine receptor subtype involved in
profibrotic activation was recognized by using selective pharmacological antagonists for each receptor subtype, in conjunction with the general agonist
NECA (5 μM). The induction of the markers fibronectin (A) and α-SMA (B) in HK2 cells, was evaluated by western blots. Selective antagonists were DPCPX
(30nM) for A1, ZM241385 (10nM) for A2A, MRS1754 (50nM) for A2B and MRS1220 for A3 (10nM) receptor subtypes. The upper images show representative
western blot detections of marker content in total protein extracts (50 μg) from treated HK2 cells. The blocking effect was assayed in HK2 cell cultures in 5mM
(left white bars graphs) or 25mM (right black bars graphs) D-glucose. The graphs represent the mean ± SD of the ratio between immune signals of fibronectin
or α-SMA vs β-actin. The ratio in HK2 cells without any pharmacological modulator was normalized to 1. * P < 0.05 versus untreated cells, # P < 0.05 versus
NECA, n = 6.
doi:10.1371/journal.pone.0147430.g004
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cellular profibrotic effects mediated by low affinity adenosine receptors. We contribute to the
emerging notion that implicates a chronic increase of adenosine with fibrotic processes.
Fig 5. An antagonist of adenosine A3 receptor blocks profibrotic activation induced by TGF-β. A. The induction of the marker fibronectin was
evaluated by western blots in HK2 cells upon exposure to TGF-β. The contribution of a particular adenosine receptor subtype in TGF-β-induced cell
activation, was recognized by using selective pharmacological antagonists. Selective antagonists were DPCPX (30nM) for A1, ZM241385 (10nM) for A2A,
MRS1754 (50nM) for A2B and MRS1220 for A3 (10nM) receptor subtypes. B. The particular contribution of the adenosine A3 receptor was evidenced by
knocking down the expression of the receptor using siRNA (siRNA A3AR). The upper images show representative western blot detections of fibronectin
content in total protein extracts (50 μg) from treated HK2 cells. The blocking effect was assayed in HK2 cells cultures 5mM (left white bars graphs) or 25mM
(right black bars graphs) D-glucose. The graphs represent the mean ± SD of the ratio between immune signals of fibronectin vs β-actin. The ratio in HK2 cells
without TGF-β treatment was normalized to 1. * P < 0.05 versus untreated cells, # P < 0.05 versus TGF-β, n = 5.
doi:10.1371/journal.pone.0147430.g005
Fig 6. Effect of high D-glucose and experimental diabetes on the adenosine receptors content. A. The effect of D-glucose exposure (24 h) on the
protein levels of adenosine receptor subtypes A1, A2A, A2B and A3 in HK2 cells was evaluated by western blot. Representative images of western blots of total
protein extracts from cells exposed to 5 and 25 mMD-glucose are shown. B. The effect of STZ-induced diabetes on adenosine A3 receptor content was
evaluated by western blot of total protein extracts from tubules isolated from control (ctr) and diabetic (db) rats following 1 or 4 months post-induction. The
graphs show quantitative analysis of immune signals. The means in controls were normalized to 1. A: n = 6, B: n = 3.
doi:10.1371/journal.pone.0147430.g006
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Indeed, experimental models have associated such elevated levels of nucleoside and adenosine
receptor activity with the progress of hepatic, dermal and pulmonary fibrosis, and recently
with chronic kidney disease [31–33].
ENT1 is the main nucleosides transporter in proximal tubules [34] and responsible for the
basolateral uptake of adenosine [21]. Extensive distribution of ENT1 throughout the kidney
indicates that this transporter plays a role in adenosine signaling beyond nucleoside and
nucleobase homeostasis [20,35]. While, decreased ENT1 activity, capable of increasing adeno-
sine levels, has been described as renoprotector in an acute kidney injury model using tissue
ischemia and reperfusion [21], the chronic reduction of nucleoside uptake could underlay DN
pathogenic fibrosis. Certainly, long term hyperglycemia concurs with decreased ENT1 activity
and increasing levels of adenosine in our experimental model. In turn, autocrine/paracrine
adenosine signaling mediates fibrotic phenotypic changes in epithelial tubule cells. This injuri-
ous loop was impeded by knocking down the A3 receptor in HK2 cells and by using a pharma-
cological antagonist in diabetic rats. These findings suggest that adenosine receptor blockers
may be useful as new therapeutic approach.
Fig 7. In vivo effects of pharmacological inhibition of A3AR.Diabetic rats were treated with the adenosine A3 receptor antagonist MRS1220 from days 31
to 60 post diabetes induction, A. Representative inmunohistochemical detection of α-SMA in cortical areas of kidney sections from untreated (control),
diabetic (vehicle-treated rats) and MRS1220-treated diabetic rats. Original magnifications 400X. B. The graph shows quantitative results derived from
staining analyses of consecutive field from three animals per group using the UN-SCANIT 2.0 software. Values of control samples were normalized to 1.
* P < 0.05 vs control.
doi:10.1371/journal.pone.0147430.g007
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There are several evidences showing that glucose levels play a role in the control of ENTs
activity [30,36–38]. Some reports recognize insulins action of counteracting decreased nucleo-
side uptake activity imposed by elevated D-glucose, through ENT1 activity rescue and increas-
ing ENT2-mediated transport [30,36–38]. Probably, these facts could link the deficient insulin
signaling and hyperglycemia in renal cells with increasing levels of the nucleoside and the path-
ogenesis of DN. It is worth noting that in glomeruli isolates from diabetic rats, extracellular
adenosine levels were considerably increased in comparison to controls however differences
were not seen for other adenine nucleotides [22]. Only sodium-independent uptake activity
mediated by ENT1 was inhibited. Probably, it became the main engine for increasing extracel-
lular adenosine, despite the fact that slight changes on AMP hydrolyzing activity have been
previously described [22].
The particular increase of plasma adenosine levels in DN patients was described in recent
years [9,10], linking the progression of renal injury with adenosine signaling. Using diverse
experimental models it has been further suggested that adenosine signaling and receptor induc-
tion are common pathogenic pathways in chronic kidney injury [33]. Thus, the adenosine
deaminase knockout (ada-/-) mice model, exhibiting augmented levels of the nucleoside
because of impeded metabolism, shows renal dysfunction and sclerosis. In addition, Dai and
collaborators demonstrated that development of renal fibrosis generated in ada-/- animals can
be avoided using an A2BAR antagonist [33]. Promising outcomes were also obtained on renal
fibrosis in mice caused by angiotensin II or unilateral ureteral obstruction (UUO) [33]. Fur-
thermore, the diabetic glomerular alterations in STZ-treated rats were ameliorated using an
antagonist of A2BAR [22], regardless of the recent proposal that A2BAR has a vascular protec-
tive effect in a model of DN [39]. Interestingly, it has recently been described the implication of
the adenosine A3 receptor subtype in mediating fibrosis in the UUO experimental model [28],
so the antagonist LJ-1888 was able to ameliorate tubule-interstitial fibrosis. Consequently, such
protective effects of antagonists of low affinity receptors A2B and A3 could come from the inhi-
bition of the pathogenic effects of adenosine differentially occurring in renal cells types since,
the induction of the A2B receptor subtype has been related to podocyte cell dysfunction,
increased TGF-β release and diabetic glomerulosclerosis [20,22] while here, we showed that the
A3 receptor may be associated with profibrotic activation of tubular epithelial cells.
The location of the A3AR subtype in the kidney has not been conclusively determined. We
found that the localization of A3AR was widely distributed in epithelial tubule cells. In
addition, we detected the A3AR protein in glomerular cells. Pawelczyk et al [40] described that
membrane-associated A3AR protein levels increased by 70% in diabetic kidney cortex and
decreased by 80% in medulla. Such increase may not be ascribed to proximal tubule cells
because we did not observe changes in the receptor content due to diabetes. Notably, the recep-
tor content was extended to tubulointerstitium in biopsies from DN patients with advanced
progression of injury. This fact suggests that with the progression of the disease the interstitium
was enriched with A3AR positive cells that could direct interstitial fibrosis. One of the mecha-
nisms involved in renal fibrosis is the infiltration of macrophages which secret several cyto-
kines underlying fibroblast activation and myofibroblast generation [41,42]. In this context,
Fig 8. Expression of ENT1 and A3AR in human kidney. A. Immunohistochemical detection of ENT1 and A3 receptor proteins were carried out in human
kidney sections from non-diabetic normal tissue and biopsies from diabetic nephropathy patients. Selected images denote representative progressive stages
of renal injury probed by the content of α-smooth muscle actin (α-SMA) and pathological analysis. Arrows indicate interstitial distribution of the immune
signal. Original magnification 200x. Scale bars 50μm. B. Representative negative control without primary antibody. Quantitative image analyses of immune
staining for ENT1 (C) A3AR (D) and α-SMA (E) in human biopsies. The graphs show quantitative results derived from staining analyses in defined areas (at
least 5 glomeruli, 10 tubules and 10 interstitium per sample) using the UN-SCANIT 2.0 software. Human biopsies from 9 diabetic nephropathy patient and 3
controls are individualized in S1 Table. Values in normal tissue samples were normalized to 1. * P < 0.05 vs normal.
doi:10.1371/journal.pone.0147430.g008
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the anti-inflammatory effect of A3AR agonists has been previously suggested [43,44]. On the
other hand, epithelial proximal tubule cells seem to be capable of transdifferentiate to a primi-
tive mesenchymal phenotype (epithelial to mesenchymal transition, EMT) in response to cer-
tain physiological cues, conducted predominantly by TGF-β [45,46]. In essence, has been
proposed these cells appear to be capable of altering their morphology, expressing myofibro-
blastic markers, and migrating through basement membrane into the interstitium, thus joining
the pool of activated fibroblasts. It is suggested that EMT contributes up to one-third of the
interstitial cells population that produce fibrotic mediators and extracellular matrix [47]. This
process has been recognized in biopsies of patients with DN [48] and strong correlations were
established between the EMT occurrence, interstitium expansion and collagen deposition
[49,50]. In fact, EMT, myofibroblastic transdifferentiation, proteinuria and the decline in renal
function are strongly correlated thus, supporting α-SMA immunostaining to monitor renal
fibrosis in diabetic patients [49,50]. Thus, the exact source of A3AR positive cells and their role
to renal fibrosis remains to be a debate.
Notably, the induction of α-SMA and fibronectin mediated by TGF-β in HK2 cells were
blocked by the A3AR antagonist, suggesting a crosstalk between adenosine and the cytokine
intracellular signaling. Consequently, it was suggested that the anti-fibrotic effect of the A3AR
antagonist LJ-1888 in the presence of TGF-β up-regulation in the UUO rats kidneys, may
account for MAP kinases inactivation [28]. It has been described that the adenosine A1 and A3
receptor subtypes share some signaling properties such as both receptors are coupled to Gi pro-
tein and could trigger MAP kinases activation [24,51]. This property could be evident when
antagonizing A1 and A3 receptor subtypes, both preventing HK2 cell transdifferentiation
under low D-glucose levels. However, the particular signaling property that implicates A3AR
with TGF-βmediated profibrotic activation, is a novel topic that remain to be elucidated.
Collectively, our data link the mechanism mediating the increased adenosine levels with the
activity of adenosine A3 receptor. This study supports the evaluation of preclinical studies to
assess the efficacy of this new alternative for the treatment of DN targeting renal fibrosis.
Supporting Information
S1 Fig. Adenosine A3 receptor knockdown blocks fibronectin induction mediated by
NECA and high D-glucose. A. The content of the adenosine A3 receptor was evaluated by
western blot in HK2 cells transfected with commercially available and validated short interfer-
ing RNAs (siRNA) from Ambion (catalogue number AM16708). Typically transfection using
100 pmol of selective siRNA decreased A3AR by 80%. B. The induction of the EMT marker
fibronectin was evaluated by western blot in HK2 cells upon exposure to NECA (5μM) and
5mM (control) or 25mM (HG) D-glucose. The particular contribution of the A3AR was evi-
denced by knocking down the expression of the receptor using siRNA (siRNA A3). The graph
represents the mean ± SD of the ratio between immune signals of fibronectin vs tubulin. The
ratio in HK2 cells in 5mMD-glucose treatment was normalized to 1. # P< 0.05 versus NECA
or HG, n = 6.
(TIF)
S1 Table. Clinical parameters of patients.
(TIF)
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